Shipment of delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), will resume following a ...

Fintel reports that on July 30, 2025, Barclays upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...

Shares of Sarepta Therapeutics ($SRPT) jumped over 14% on Tuesday after the FDA authorized the company to restart shipments ...

Moderna CEO Stéphane Bancel said in an email to employees that the company made "every effort" to avoid layoffs that will ...

Other changes under Prasad, who was also the agency's chief medical and science officer, included a new policy limiting the ...

Dr Vinay Prasad has resigned from the FDA after less than three months amid controversy over Sarepta Therapeutics' gene ...

But this time, the unknown is hitting the industry in a different way from when Prasad was tapped to lead CBER less than ...

The former official, Vinay Prasad, had been on the job three months and had recently come under attack by conservative ...

The immediate ebullient reaction to Vinay Prasad’s ouster is understandable, and may ultimately be the correct one, Adam ...

Donald Trump reportedly ignored calls from Health Secretary Robert F. Kennedy Jr. not to fire the top vaccine official at the Food and Drug Administration after a pressure campaign from far-right ...

Alnylam Pharma raised its revenue outlook as its heart drug sees quick uptake.

Dr. Vinay Prasad is stepping down as the Food and Drug Administration’s top vaccine regulator after a brief tenure. A ...